Trial · NCT01005407
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects Who Have a Seroprotective Immune Response | HEPLISAV and Placebo | 90.1 | Percentage of participants | ||
| Percentage of Subjects Who Have a Seroprotective Immune Response | Engerix-B | 70.5 | Percentage of participants | ||
| Percentage of Participants With Local and Systemic Reaction to Injections | HEPLISAV and Placebo | Local reaction: Injection 1 | 24.33 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | Engerix-B | Local reaction: Injection 1 | 18.87 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | HEPLISAV and Placebo | Local reaction: Injection 2 | 23.10 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | Engerix-B | Local reaction: Injection 2 | 16.16 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | HEPLISAV and Placebo | Local reaction: Injection 3 | 0 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | Engerix-B | Local reaction: Injection 3 | 13.84 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | HEPLISAV and Placebo | Systemic reaction: Injection 1 | 22.34 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | Engerix-B | Systemic reaction: Injection 1 | 22.64 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | HEPLISAV and Placebo | Systemic reaction: Injection 2 | 16.38 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | Engerix-B | Systemic reaction: Injection 2 | 18.10 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | HEPLISAV and Placebo | Systemic reaction: Injection 3 | 0 | percentage of participants | |
| Percentage of Participants With Local and Systemic Reaction to Injections | Engerix-B | Systemic reaction: Injection 3 | 13.39 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01005407/results